Jim is currently the CEO, Founder and Chairman of Klotho Therapeutics (KTI) which is developing modified human Klotho protein/hormone for the prevention and treatment of kidney diseases and the major diseases of aging including cancer, diabetes, neuro-degenerative diseases, and human frailty. 

Jim has been Investing for almost 20 years primarily in early stage technology and life science companies with 100X return potential with a particular interest in extending Health Span and addressing the major diseases of Aging including Alzheimers, Kidney Disease, Cancer, Diabetes, and human frailty. Many investments have successfully achieved over 10X return and several over 100X return.

Jim’s motivation to pursue treatments for chronic diseases of aging began over 30 years ago when he learned his father had a genetic disorder called Polycystic Kidney Disease (PKD).  Unfortunately, at that time testing for this disease was not common, and his father’s PKD was not discovered in time to delay kidney failure. Despite a successful kidney transplant, he later died of cancer.